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AbstrAct
Objective To inform the development of a core outcome 
set for eczema by engaging with people with eczema 
and parents of children with eczema to understand their 
experiences and understanding of the concept ‘eczema 
control’.
Design 37 participants took part in a total of six semi-
structured online focus groups held in a typed chatroom 
with 5–7 participants per group. Three groups involved 
adults with eczema and three groups involved parents of 
children with eczema. Framework analysis was used for 
data analysis.
setting A community-based sample was recruited from 
across the UK via social media and email.
Participants 19 adults aged 17–61 years (15/19 female, 
16/19 white) and 18 parents of children with eczema aged 
9 months–17 years (9/18 female, 18/19 white).
results Four main themes were identified: 
(1) ‘Commonalities and differences in the experiences 
of control’: a reduction in symptoms such as itch and 
sleep loss characterised eczema control, but what level 
was acceptable differed across participants;(2) ‘Eczema 
control goes beyond the skin’: psychological factors, 
social factors, the constant scratching and the impact 
on everyday activities are a variety of ways an individual 
can be impacted;(3) ‘Stepping up and down of treatment’: 
participants’ stepped-up treatment in response to loss of 
control, but several factors complicated this behaviour. 
Control needed to be maintained after stepped-up 
treatment ended to be acceptable; and (4) ‘How to 
measure control’: self-report was generally preferred to 
allow frequent measurements and to capture unobservable 
features. Although most thought their eczema needed to 
be measured frequently, many also felt that this was not 
always realistic or desirable.
conclusions ‘Eczema control’ is a complex experience 
for people with eczema and parents of children with 
the condition. These experiences could have important 
implications on how long-term control should be measured 
in eczema clinical trials and clinical practice.
IntrODuctIOn
Eczema is characterised by periods of remis-
sion and relapse.1 An international survey of 
2002 patients and caregivers found that 75% 
rated being able to effectively control their 
eczema as the most important improvement 
to their quality of life.2 ‘Long-term control’ 
has been voted as one of the four domains 
in the core outcome set for eczema clinical 
trials by the Harmonising Outcome Measures 
for Eczema (HOME) initiative.3 There is 
currently no consensus on what is meant 
by ‘long-term control’ of eczema, but it is 
recognised that it is important to consider 
the patient perspective in outcome measures 
in eczema.4 Therefore, this study explores the 
‘When it goes back to my normal I 
suppose’: a qualitative study using 
online focus groups to explore 
perceptions of ‘control’ among people 
with eczema and parents of children 
with eczema in the UK
Laura M Howells,1 Joanne R Chalmers,1 Fiona Cowdell,2 Sonia Ratib,1 
Miriam Santer,3 Kim S Thomas1
To cite: Howells LM, 
Chalmers JR, Cowdell F, 
et al.  ‘When it goes back 
to my normal I suppose’: a 
qualitative study using online 
focus groups to explore 
perceptions of ‘control’ 
among people with eczema 
and parents of children with 
eczema in the UK. BMJ Open 
2017;7:e017731. doi:10.1136/
bmjopen-2017-017731
 ► Prepublication history and 
additional material for this 
paper are available online. To 
view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2016- 
017731).
Received 15 May 2017
Revised 7 July 2017
Accepted 16 August 2017
1Centre of Evidence Based 
Dermatology, University of 
Nottingham, Nottingham, UK
2Faculty of Health Education and 
Life Sciences, Birmingham City 
University, Birmingham, UK
3Primary Care and Population 
Sciences, University of 
Southampton, Southampton, UK
correspondence to
Laura M Howells;  
 laura. howells1@ nottingham. 
ac. uk
Research
strengths and limitations of this study
 ► We used qualitative research methods to incorporate 
perspectives of people with eczema and parents of 
children with eczema into discussions informing the 
development of a core outcome set.
 ► Explored understandings of the widely used term 
‘eczema control’ from the perspective of people with 
eczema and parents of children with eczema.
 ► This study used online focus groups, which is 
a relatively novel methodology that expands on 
traditional methods for involving patients and 
parents in the development of outcome measures.
 ► The online focus groups limited the ability to 
probe more deeply into participants’ experiences 
compared with face-to-face focus groups.
 ► The sample mainly included individuals who had 
attended secondary care for their eczema or their 
child’s eczema so it may not represent the views of 
people living with milder disease who are managed 
in primary care.
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patient perspective of ‘long-term control’ and adopts the 
language used by patients to discuss this concept, which 
were most commonly ‘control’ and ‘flares’.
A systematic review of methods to capture long-term 
control revealed heterogeneity in how control was 
captured in published randomised controlled trials 
(RCTs).4 Ninety-one per cent of RCTs used repeated 
measurement of eczema outcomes such as clinical signs, 
quality of life and itch.4 Other ways of measuring long-
term control focused on assessment of use of eczema 
medications (27% of RCTs) and flares (25% of RCTs).4 
The review highlighted that measuring ‘flares’ may not 
be the only method for capturing the long-term control 
of eczema.
The standardised definition and core outcome measure 
of long-term control should be driven by patients’ and 
parents’ experience, as they are best placed to understand 
whether their disease is being controlled.5 Using qualita-
tive research in the development of a core outcome set can 
enable meaningful representation of all stakeholders.6 
Previous qualitative research has explored the impact 
of eczema, information needs, attitudes to self-care and 
views on treatment of parents of children with eczema.7–12 
However, very little is known about what people under-
stand by the widely used term eczema ‘control’, hence a 
post-meeting questionnaire of the HOME IV delegates 
indicated that qualitative work to establish what long-
term control means to patients was an important research 
priority for the long-term control working group.13
study objectives
To engage people with eczema and parents of children 
with eczema to:
1. determine what long-term control means to them
2. explore what aspects of long-term control are most 
important to them
3. explore what methods of measuring long-term control 
are feasible and acceptable.
MethODs
All participants provided online consent prior to partici-
pation. The protocol is on the Centre of Evidence Based 
Dermatology’s website (http://www. nottingham. ac. uk/ 
research/ groups/ cebd/ resources/ protocol- registration. 
aspx).
Participant selection
Inclusion criteria were adults aged ≥16 years with 
self-reported eczema and parents of children with 
parent-reported eczema. Participants were recruited 
through the National Eczema Society Facebook page, 
Twitter posts and email invitations to people who had 
consented to being contacted for eczema research and 
on the University of Nottingham website. All those 
who expressed an interest in the study were sent an 
online survey. Based on the survey responses, purpo-
sive sampling was used to maximise variation in partici-
pants relating to characteristics of self-reported eczema 
severity, ethnicity, age, sex, previous participation in 
clinical trials, disease duration and previous experi-
ence of healthcare services.14
Procedure
Six semi-structured, synchronously typed, online focus 
groups were conducted between August and October 
2016. Online methods are becoming increasingly popular 
in health research due to their ability to reduce costs and 
the widespread availability of internet access. Predomi-
nantly, online-type focus groups have been asynchronous 
in nature (not occurring in real time).15 While asynchro-
nous methods may allow for wider participation, they 
have been criticised as not being sufficiently responsive 
to be considered a ‘focus group’.16 Previous studies using 
synchronous online focus groups have found that the 
immediacy and dynamism of face-to-face conversations 
was mimicked.17 18
Participants were allocated to one group only. Groups 
included either adults (16 years or over) who had eczema 
or parents of children with eczema. The recruitment 
procedure is outlined in figure 1. Participants joined a 
group hosted on www. chatstep. com from a location of their 
choice. Participants entered a nickname of their choice 
and the room name and password that were provided 
by email. Between two and four female researchers 
were present at the discussion to do tasks such as time-
keeping, ensuring all participants remained included, 
responding to technical issues, reading responses and 
typing responses. LMH and one other researcher (JR, 
KST or SR) logged into each group to facilitate. All of the 
research team were introduced simply as ‘researchers’, 
although FC is a registered nurse and MS is a general 
practitioner. KST has had previous experience facilitating 
online focus groups. Four participants knew some of the 
researchers prior to the discussions due to involvement in 
other research activities. LMH established a relationship 
with the participants prior to the discussion via email and 
sometimes telephone contact. Sessions lasted approxi-
mately 70–80 min.
Focus groups followed a common topic guide (final 
topic guide in supplementary materials). The questions 
were revised iteratively based on what was perceived as 
facilitating engagement and relevant responses during 
the focus groups (eg, stopped asking participants to think 
about going for a check-up as this raised health service 
issues that were not the subject matter of the study). 
Questions were framed to elicit everyday experiences of 
people living with eczema.
The transcript was downloaded after each session. 
LMH made field notes during and after discussions 
to reflect on her thoughts and feelings relating to the 
data.19 Participants were sent a debrief email and asked 
to provide feedback on their experience of taking part 
shortly after the group. In April 2017, participants were 
sent a summary of the results and asked for their feed-
back on the results.
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Figure 1 Recruitment procedure.
Patient and public involvement
The topic guide was developed with input from two 
parents of children with eczema and two adults with 
eczema, three of whom then participated in a group. A 
ranking activity posted via Twitter (n=75) and input from 
the Centre of Evidence Based Dermatology patient panel 
helped us decide what language to use to discuss ‘long-
term control’ in advertisements and information about 
the study, but the language participants used was subse-
quently adopted.
Analysis
Framework analysis was used to analyse transcripts.20 
Themes were identified at the semantic level, and analysis 
was conducted in an essentialist/realist framework.21 LMH 
conducted the analysis, but other team members were 
involved in refining, interpreting and mapping themes. 
The thematic framework was driven by familiarisation with 
the transcripts; however, some pre-existing concepts from 
the literature were considered when developing the frame-
work. Themes were indexed using NVivo V.11. The frame-
work was altered to best fit the data. Framework matrices 
were developed and used for interpreting and mapping 
the data. No new themes were identified in the final two 
groups so the researchers were confident data saturation 
had occurred to the point that additional groups would 
not have modified the thematic framework.22
results
Participant characteristics
Table 1 summarises participant characteristics (n=37). 
The majority of participants had been seen in secondary 
care (had been referred to a hospital specialist) for their 
eczema (n=34/36, 94%). A minority had taken part in 
clinical trials (n=4/37, 11%).
Feasibility and acceptability of online focus groups
Out of participants that had provided consent and signed 
up to a group, the attendance rate was 37/49. Eleven of 
37 participants provided feedback on their experience of 
taking part in the online focus group. Participants liked 
the convenience of the online method.
Preferred online discussion, much more convenient, 
no need for childcare. (Participant 29, group 5, 
parent to son, aged 9 months)
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Table 1 Summary of participant and child demographics
Adults with 
eczema
Parents of 
children 
with eczema
Children 
with eczema 
(reported by 
parents who 
participated)
N of participants 19 18 –
Sex, n (%)
  Male 4 (21) – 9 (50)
  Female 15 (79) 18 (100) 9 (50)
Age in years, n (%)
  ≤5 – – 12 (67)
  6–11 – – 5 (27)
  12–15 – – –
  16–25 6 (31.67) 1 (6) 1 (6)
  26–40 6 (31.67) 15 (83) –
  >40 6 (31.67) 2 (11) –
  Unknown 1 (5) – –
Ethnicity, n (%)
  White 16 (84) – 17 (94)
  Asian 1 (5) – –
  Black – – –
  Mixed 2 (11) – 1 (6)
Years since eczema diagnosis, n (%)
  <5 1 (5) – 12 (66)
  6–11 2 (11) – 4 (22)
  12–15 – – –
  16–25 5 (26.34) – 1 (6)
  26–40 5 (26.34) – –
  >40 5 (26.34) – –
  Unknown 1 (5) – 1 (6)
Self or parent reported current disease severity, n (%)
  Clear 2 (11) – –
  Almost clear 2 (11) – 2 (11)
  Mild 4 (21) – 4 (22)
  Moderate 9 (47) – 7 (40)
  Severe 1 (5) – 5 (27)
  Very severe 1 (5) – –
However, some parents were distracted or unable to 
attend the evening groups (18:30–20:00) due to their 
children’s bedtime coinciding with the discussion.
I have a screaming tired 3 year old so let’s see if we can 
do bedtime simultaneously with all her zinc wraps etc 
ha! Prob not wisest choice of times oops! (Participant 
12, group 2, parent to daughter, aged 3 years)
Participants liked the group size, privacy and modera-
tion by the researchers. The method provided anonymity 
and a non-intimidating platform for all voices to be heard.
I thought the discussion group was well moderated 
and focused, and gave everyone ample opportunities 
to contribute - and allowed time to think and send 
responses. (Participant 1, group 1, male, aged 
33 years)
The chatroom indicated when individuals were typing, 
so the facilitators tried to ensure everyone had responded 
before advancing discussion. However, typing abilities 
differed and some said the conversation moved too slowly, 
while others found the conversation pace to be fast.
I think the only negative was the conversation became 
a bit disjointed at times, as it took people time to type. 
I don’t however know how you could address this. 
(Participant 28, group 5, parent to daughter, aged 
5 years)
Main themes on long-term control of eczema
Figure 2 shows how themes 1–3 relate to patient and 
parent experiences and understanding of eczema 
‘control’, which informs how it should be measured 
(theme 4).
theme 1: commonalities and differences in the experiences of 
control
Normal or out of the ordinary for me
Increased itching, increased redness and less sleep were 
often cited as indicators of a treatment not working. 
However, some participants expressed how their symp-
toms, or their child’s symptoms, of uncontrolled eczema 
have altered over time.
I have found some treatments help but he then 
presents with different types of eczema. Sometimes 
dry and cracked, other times wet and blistery, some 
times is spotty and other times is patchy. (Participant 
9, group 2, parent to son, aged 7 years)
Individuals had different thresholds of acceptable level 
of control. For some, control was only achieved when 
there were no symptoms, while many viewed control as 
a reduction in their symptoms to what was ‘normal’ for 
them. For example, one participant described their 
normal as ‘just mild pigmentation marks’. The variation in 
‘normal’ for each individual has important implications 
for measuring control.
Establishing a baseline of what’s ‘normal’ for the 
person and how this is deviated from – because it 
is different for everyone! (Participant 2, group 1, 
female, aged 23 years)
Flares vary in size and timing
Variations in the severity of flares were apparent in 
descriptors of size such as ‘small flares’ and ‘big flares’. The 
length of flares also varied both between and within indi-
viduals. Some described flares lasting hours, a day or a 
few days, while others described flares that lasted months.
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Figure 2 Mapping of the thematic framework.
If I catch a minor flare quickly enough I can sometimes 
control the irritation before it get completely out of 
control to what I call a meltdown. (Participant 5, 
group 1, female, aged 20 years)
The speed of onset of a flare was varied between 
individuals and changed for some individuals over 
time. Flares were often described as sudden in onset 
with limited early signs, while others described how 
the build-up could be gradual. Some parents said their 
child will know before them that a flare is coming, 
which could indicate that onset appears quicker for 
some parents as they do not always notice earlier 
indicators.
The end of a flare was characterised by better sleep, 
itching gone or not bleeding on their bedsheets. However, 
a few commented how it was hard to determine the end 
of a flare as it never fully went away.
With the eczema being so severe a flare never truely 
ends, it just is better. (Participant 7, Ggroup 2, parent 
to son, aged 3 years)
theme 2: eczema control goes beyond the skin
Psychological impact
Periods of uncontrolled eczema were characterised by 
low mood for adults, children with eczema and parents. 
Parents used emotive language to describe how they felt 
about periods of uncontrolled eczema but reported the 
psychological impact on their child in broad terms of 
how it affected the child’s general demeanour. The level 
of control was said to result in either a ‘happy child’ or a 
grumpy/distressed child.
Total change in mood. She is happier, carefree and is 
not frowning. She can play more as not scratching all 
the time. She sleeps and is not grumpy, less tantrums 
as rested, able to concentrate and have patience due 
to sleeping well. (Participant 13, group 3, parent to 
daughter, aged 3 years)
Some groups discussed how flares were accompanied 
by apprehension due to lack of certainty of how bad the 
flare would be and how long it would last. A few partici-
pants also recalled that even when they were better they 
were apprehensive of a flare returning.
…fear that it will come back after it’s got better is 
always there. (Participant 34, group 6, female, age 
unknown)
The vicious itch/scratch cycle
Itchiness to the point that it was difficult not to scratch 
equated to uncontrolled eczema for many participants.
I couldn’t even go to the toilet as he would be 
scratching, face weeping, awful. (Participant 29, 
group 5, parent to son, aged 9 months)
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Scratching was said to often make the eczema worse, 
often leading to more itchiness, broken skin and bleeding, 
described as a ‘vicious cycle’ that needed to be broken to 
regain control.
It feels good to itch – a temporary relief! Although 
you know it is making it worse! (Participant 36, group 
6, female, aged 41 years)
Affects ability to do activities of daily living
Uncontrolled eczema could impact almost every aspect 
of people’s lives. Sleep disturbance had an impact on 
concentration the next day. Itchiness and needing to 
scratch also impaired concentration; however, it was clear 
that tiredness exacerbated this problem.
I used to go into work on one hour’s sleep…and 
then I’d spend my time staring into space, itching, 
feeling sorry for myself and unable to snap out of it. 
(Participant 35, group 6, female, aged 25 years)
Uncontrolled eczema and the sleep loss it causes 
affected the child’s behaviour as well as their concentra-
tion. For example, the child was described as ‘grumpy’ and 
having ‘tantrums’.
Another challenge was the time consumed during a 
flare period because of what they needed to do differently 
to normal, although some participants suggested the 
burden was not limited to flare periods as they engaged 
in activities to prevent flaring that were also very time 
consuming.
Adults often felt restricted in clothing due to irritation 
that certain clothes caused, wanting to cover eczema 
with clothing, visibility of blood on light fabrics and flaky 
skin on dark fabrics. Some parents altered their child’s 
clothing, which related to irritation rather than concerns 
about the visibility of the eczema.
I guess what you might be doing differently because 
of your eczema. Like clothes… covering up eczema, 
not black because of dry skin, not too light because 
I might itch and bleed. (Participant 34, group 6, 
female, age unknown)
Washing and exercise were problems for many adult 
patients due to being unable to face the sensations when 
cracked or dry skin came into contact with water or sweat. 
Parents expressed concern about their child’s ability to 
learn, play and interact.
Several adults and parents said impairment to move-
ment was one of the biggest problems faced. Eczema 
around joint areas, feet or hands impaired their ability 
to move and do things. Movement was often described 
as painful.
Affects you socially
Some adults with uncontrolled eczema reported ‘embar-
rassment’ and ‘social anxiety’. One group suggested this 
effect was increased when the eczema was more visible.
Embarrassing? I often tend to avoid eye contact, as 
I’m embarrassed with what people might see…and 
think. I’ve lost count of the times that I’ve been asked 
things like ‘Who beat you up?‘, ‘Dud you cut yourself 
shaving’, and ‘Ugh, is that contagious?’. (Participant 
18, group 4, male, aged 43 years)
Both adults and parents expressed feelings of isolation 
due to the lack of shared experience and understanding 
from others, rather than from direct social exclusion 
(although this was apparent for one participant). Some 
parents expressed concern for their and their child’s 
physical isolation due to preventing exacerbations and 
treating the eczema reducing socialisation opportunities.
How they interact, their developmental markers, how 
much socialisation they get, for us when his skin is 
bad it’s the socialising and getting out of the house 
that suffers. (Participant 27, group 5, parent of a 
male child, aged 16 months)
theme 3: stepping up and down of treatment
Responding to a loss of control by ‘stepping-up’ treatment
Most participants altered treatment depending on the 
level of eczema control. Many ways of measuring control 
relating to treatment changes were mentioned, including 
number of treatment prescriptions, use of extra treat-
ments, use of higher strength treatments, time spent 
using treatments, frequency of treatment and amount of 
treatment used.
While most discussed visiting the doctor to seek treat-
ment if the eczema was not controlled, stepping-up 
treatment was complicated by various factors. Not all 
participants visited a healthcare professional to step-up 
treatment. Many would use stronger creams they had 
at home or increase the amount used of the treatment 
they are already prescribed. Participants often wanted to 
step-up treatment promptly to prevent further exacerba-
tion of the eczema, but a few felt their doctor did not 
understand this urgency and would sometimes delay or 
avoid giving certain prescriptions.
However, some participants were reluctant to change 
their treatment in response to worsening of the eczema. 
Some were fearful that if they use the strongest treat-
ment available, they may have nothing left to use if it 
gets worse. There were beliefs that a treatment would 
eventually stop working if you used it too much. Some 
did not change their treatment as they wanted to try 
non-pharmacological solutions such as exercise, diet 
and silk sleeping suits for children. However, sometimes 
these methods were used in combination with pharma-
cological treatments.
With that in mind we have been trying a lot of other 
things and we have been reducing the creams down 
as much as possible so they will be at maximum 
effectiveness for flare ups, It’s a scary prospect isn’t  
it - having nothing to use as an alternative! (Participant 
25, group 5, parent of daughter, aged 11 months)
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Treatment needs to maintain control in the long term
It was discussed that control has been gained or a flare has 
come to an end when you could return to maintenance 
routines and the eczema symptoms remained controlled.
I usually think a flare has ended if I’ve not had to 
put steroid cream on that day (Participant 1, group 1, 
male, aged 33 years)
Alternatively, if the worsened eczema returned once 
stepped-up treatment was ended, this was not considered 
to be long-term control. Some participants described a 
continuous cycle of stepping-up and stepping-down treat-
ment where the eczema did not remain improved when 
returning to maintenance treatments. However, it was 
thought some participants were searching for a ‘cure’ 
rather than ‘control’.
Sometimes we are advised to use steroids for x long… 
then as soon as stops everything flares up again. Not 
a long term solution really. (Participant 29, group 5, 
parent to son, aged 9 months)
theme 4: how to measure control
Suggested features of long-term control to be measured 
were diverse. They can be categorised as observable 
signs or symptoms (eg, redness), unobservable symp-
toms (eg, itch), treatment used (eg, escalation of treat-
ment), scratching (eg, number of times scratched) the 
effects on the individual’s life (eg, ability to do everyday 
activities) and the psychosocial impact (eg, general 
mood).
It has to be you
Participants unanimously thought measures should 
include self-report. Measurement by a doctor was 
suggested to be too infrequent to capture the fluctuations 
in eczema.
Again it depends on each child, but certainly 
more frequently than the usual 3 months between 
consultants visits. We can be fine in the morning as 
horrendous by bedtime. (Participant 30, group 5, 
parent of male child, aged 11 years)
Self-report was also preferred because doctors assess 
the physical aspects of eczema and not how it affects the 
individual beyond this. The broad array of ways it can 
affect individuals is illustrated in theme 2.
Has to be you. SO subjective a topic, and nurses’ 
doctors can only observe so much - and not the effects 
it has personally! (Participant 2, group 1, female, 
aged 23 years)
Some participants suggested they need to be able to 
make comparisons with previous levels of control for 
self-report to be meaningful. This links to theme 1, where 
it was discussed how everyone has different experiences 
of ‘normal’.
It’s usually ‘compared to what’, or on a scale of 1–10, 
where no number has a real meaning. (Participant 
22, group 4, female, aged 31 years)
Other concerns with self-report included forgetting 
how the eczema has been if measurements are far apart 
(ie, looking back over the last month would be difficult) 
or ‘kidding’ themselves their eczema is better. Some 
participants suggested a measure should be quantifi-
able and percentage of body involvement was suggested. 
Others thought percentage of body affected would not 
capture the severity of an area affected or if they felt more 
burdened by eczema on certain body parts.
Photographs of skin were frequently used. This may 
seem surprising since participants highlighted the impor-
tance of looking beyond the visual effects of eczema, 
but it was used to show doctors the eczema fluctuations 
between visits. Another use for photographs and diaries 
was self-reflection on eczema changes. Numerous partici-
pants said reflecting on how the eczema used to be worse 
helped them cope. A few were concerned photographs 
may not show the eczema properly.
Ideal versus realistic frequency of measurement
Participants varied hugely in how often their eczema 
or their child’s eczema needed to be measured from 
‘how about 24 hours watch!!!’ to every few months. For 
many participants at least daily was deemed necessary to 
capture a full picture of the disease. However, many felt 
that the frequency necessary would not be easily achieved 
for them due to the burden of recording eczema activity. 
Reasons for this included being too busy, forgetting or 
not being disciplined enough.
but to be honest don’t have time when I am a busy 
working mother, sometimes it only gets a glance. 
(Participant 4, group 1, female, aged 50 years)
Analysing group interactions showed parents wanting 
to appear willing to help. Therefore, parents were some-
times hesitant to share their reservations with measuring 
the eczema too frequently, but when prompted with 
suggestions from previous groups, they did share this 
concern.
While a few were prepared to measure controlled 
eczema, many were prepared to measure at frequent inter-
vals during a flare, but not when eczema was controlled. 
They did not want to be reminded of the eczema, whereas 
during a flare they would measure it because they cannot 
help thinking about it.
It’s all you think about when it’s bad so you’d be 
prepared to do anything to make it better, like 
recording its current state, If it was in a bad condition, 
probably 30 min a day but when it’s improved I 
would rather not think about it, so maybe 10 min. 
(Participant 33, group 6, female, aged 17 years)
Some suggested frequency should change depending 
on the stage of treatment. It was thought it would be more 
group.bmj.com on November 16, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
8 Howells LM, et al. BMJ Open 2017;7:e017731. doi:10.1136/bmjopen-2017-017731
Open Access 
necessary to understand fluctuations in periods of uncer-
tainty (eg, just starting a new treatment and just ending 
a treatment).
To overcome the problem of the ideal measurement 
not being realistic, a few suggestions were made that 
frequency could be flexible to the individual’s needs or 
measuring tools could be designed so you could skip 
questions if not needed.
Participant feedback on results
Four participants provided feedback on the results. All 
found the analysis to be accurate and insightful. One 
participant reiterated their belief that an assessment of 
‘baseline’ and ‘flaring’ should include a holistic appraisal 
of lifestyle, including mental well-being.
DIscussIOn
Main findings
Conducting online focus groups allowed us to explore 
the experiences and understanding of eczema ‘control’ 
among people with eczema and parents of children 
with eczema across the UK. A loss of eczema control can 
have varied consequences and impact for an individual 
and their family: itching, scratching, sleep loss, redness, 
bleeding, impaired psychological well-being, feelings 
of fear and apprehension, impaired daily functioning, 
social isolation and societal pressures were all promi-
nent features of uncontrolled eczema. While some of 
these experiences have been reported elsewhere, this 
study specifically helps us understand how these experi-
ences relate to the concept of ‘control’.7–12 Dissatisfaction 
with treatment that did not lead to controlled eczema 
once the treatment was stopped mirrors interviews with 
parents that found dissatisfaction with the trial-and-error 
approach to eczema treatment in primary care.11
The language used to discuss ‘long-term control’ can 
vary. ‘Long-term control’ is a combination of two concepts: 
the timeframe and disease activity. There has been inter-
national consensus that long-term control should be 
measured in a clinical trial of eczema treatment that is 
3 months or longer in duration. We did not discuss the 
trial context with participants in these focus groups as we 
were interested in their individual and everyday experi-
ences. Participants spontaneously used the term ‘control’ 
during discussions. Participants also frequently used the 
terms ‘flare’/‘flare-up’, but what experiences constituted 
a flare was highly variable. Some people had ‘chronic’ 
flares lasting for months, whereas some lasted hours or 
days.
The most common way of measuring long-term control 
in published RCTs has been repeated measures of clini-
cian-reported signs, usually on a monthly basis.4 Partic-
ipants talked about how they would measure control as 
repeated measures of various factors such as quality of 
life, itch or mood. They preferred self-reported measures 
due to not all effects being observable by a doctor and 
frequent measures needed to capture fluctuations in 
eczema more fully. There are some patient-reported 
outcome measures that have been previously developed 
for use in eczema clinical practice and research, but they 
may not be sufficient to capture all aspects of eczema 
control from a patient perspective.23–26
Published RCTs have measured flares using number of 
flares, time to first flare and, to a lesser extent, duration 
of a flare or remission period.4 The size and length of 
flares could differ substantially and have varying effects 
on the individual, which highlights how measures only 
capturing frequency or length of flares would not capture 
the impact each flare has on an individual.
Treatment escalation has been used to measure flares 
and long-term control. Two studies have defined a flare 
as being: ‘an episode requiring escalation of treatment 
or seeking additional medical advice’.27 28 This measure 
had good face validity and construct validity.29 However, 
concerns around resource intensive data management 
and difficulties pooling data may mean this measure is 
not suitable for all trials.29 A similar definition has been 
proposed by the European Task Force on Atopic Derma-
titis: ‘acute, clinically significant worsening of signs and 
symptoms of atopic dermatitis requiring therapeutic 
intervention’.30 Another concept of long-term control 
that has been adopted from asthma research is the 
concept of well-controlled weeks. A well-controlled week 
has been defined as occurring when treatment ‘escalated’ 
for 2 days or fewer plus 2 or more days with a severity score 
of less than 4 out of 10. While well-controlled weeks have 
been shown to be valid and reliable, collection requires 
frequent completion of diaries that may not be suitable 
for use in all trials.31
While participants did escalate treatment in response 
to a flare, there were a number of complexities that could 
make this difficult to implement as a measure in all trials. 
The Necessity-Concerns Framework suggests patients 
hold beliefs about how necessary a treatment is to main-
tain their health and concerns about the treatment 
having adverse effects, both of which can influence treat-
ment adherence.32 Beliefs expressed by some participants 
in this study suggest they are concerned about their medi-
cation as they were reluctant to step-up treatment. There-
fore, lack of treatment adherence may present a problem 
for using treatment as an indicator of eczema ‘control’. 
Alongside changes to treatment, a behavioural response 
to loss of control many participants cited and suggested 
measuring was increased scratching, which is one method 
that has been considered as a way of measuring long-term 
control.33 34
strengths and limitations
To our knowledge, this is the first qualitative study to 
consider long-term control of eczema from a patient and 
parent perspective. The online focus groups reduced 
barriers of geographical location and time constraints and 
removed costs for travel, venue and transcription. Previ-
ously, online focus groups have been cited as enabling 
participation by people with visible skin conditions who 
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box seven key findings that could inform the 
measurement of long-term control.
From these findings, we recommend the following seven topics may 
want to be taken into consideration when deciding how to measure 
long-term control of eczema:
1. The need to scratch uncontrollably, the psychological impact, the 
social impact, symptoms (including itch, pain, sleep), impaired 
movement, the ability to do everyday activities and treatment used 
were all indicators of level of control.
2. Understanding the baseline of what is normal for an individual was 
considered important for understanding control.
3. Not everyone with eczema experiences ‘flares’ or finds it easy to 
notice changes in their eczema.
4. The behaviour of stepping-up treatment for a flare was common 
but was complicated by factors such as difficulty getting a 
prescription and concerns about stepping-up treatment when 
already using maximum treatment available.
5. For some participants taking treatments that are recommended 
for short-term use, lack of control referred to ‘rebounds’ after the 
treatment ends. Long-term control measurement should take into 
account control both during and after treatment.
6. The patient/parent perspective was considered important to fully 
capture control. The use of parents as a proxy for reporting in 
young children was not questioned by parents.
7. The acceptance of measurement frequency varied between 
participants and for an individual over time depending on lifestyle 
and commitments, the treatment stage and level of disease 
control.
lack the confidence to attend a face-to-face focus group.4 7 
This is supported by feedback from participants that they 
liked the anonymous and inclusive nature of the group.
There was a predominance of people of white British 
ethnicity and of female adults with eczema, despite 
targeted efforts to recruit male and ethnic minority 
participants. Online recruitment meant that we relied 
on self-report of eczema diagnosis and eczema disease 
severity. Only two participants reported never having seen 
a hospital doctor for their eczema, therefore the sample 
under-represents experiences for participants treated in 
primary care, which is the majority of eczema patients in 
the UK.35
Online methods present distinct challenges for qual-
itative research. Language needs to be clear as there is 
no voice intonation or non-verbal cues. Prior preparation 
of questions allowed precision in phrasing. Participants 
valued that typing allowed them to provide consid-
ered answers. Threading, where multiple strands of 
conversation occur in parallel, is typical of online focus 
groups.17 18 36 Addressing an individual’s comment while 
simultaneously inviting the whole group to comment on 
that specific point helped to maintain a coherent discus-
sion and allow further exploration of the topic.
Qualitative research has the potential to develop both 
breadth and depth of knowledge.6 Breadth is required 
to understand the scope of the experience and depth 
enables understanding the detailed complexities of 
the experience.6 The method tended to produce brief 
responses, but prompting was successful at eliciting 
more detailed responses. Reading responses was difficult 
when the discussion moved quickly, so having multiple 
researchers available to engage in different tasks was 
beneficial. Eleven participants provided feedback on the 
methodology; however, only four provided feedback on 
results. However, all feedback suggested they found the 
results to be an accurate representation of the discussion.
This study was concerned with individual experi-
ences, whereas RCTs are analysed as group aggregates 
of outcomes. Future studies need to assess the optimum 
frequency of measuring outcomes in RCTs. This study 
highlights that the benefit gained by capturing intrapa-
tient variation needs to be balanced against the burden 
of collecting this information.
Implications for research and clinical practice
This study investigates an aspect of eczema that has been 
under-researched from the patient and parent perspec-
tive. Box highlights the important ways this study may 
inform decisions on the best way to measure long-term 
control in people with eczema.
These findings will inform consensus discussions for 
development of a core outcome set for eczema clinical 
trials through the HOME initiative (www. homeforec-
zema. org).
This study is the first stage of an international qualita-
tive research project that will aim to understand long-term 
control of eczema for patients and parents in different 
countries to ensure that what is important to patients 
about the long-term control of eczema is an international 
perspective. The methodology is globally accessible and 
facilitates composite analysis to identify differences across 
countries. Since online focus groups are a relatively novel 
method, the lessons learnt from this study will provide 
guidance for international collaborators.
cOnclusIOns
This qualitative study has shown the complexity of the 
experience of long-term control for patients and parents. 
‘Eczema control’ can have a variety of meanings for people 
with eczema and parents of children with eczema, which 
has important implications for how long-term control 
may be measured. Overall, this pragmatic online research 
method was embraced by participants and enabled qual-
itative research to be conducted effectively with limited 
resources.
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